English

BOUNDLESS BIO, INC.

EDGAR

BOLD Registration statement (S-4) · filed 2026-10-08

13 filing records in this dataset, filed from 2024-03-06 to 2026-10-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Cash and cash equivalents: 20.2 million USD 2026-06-30 Source
Exact value

20213000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 22.5 million shares 2026-06-30 Source
Exact value

22475000 shares

Reported share-count change

0.40% · 89 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

22386000 shares · 2025-06-30· Source
22475000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-64 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -13879000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -58197000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -45312000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -13555000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -23693000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-56.2 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -36600000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -26359000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -46700000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -36600000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -15000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -35900000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -15000000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

485 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 122000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 107000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 546000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 122000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 46000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-56.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -36600000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -26359000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -46700000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -36600000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -15000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -35900000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -15000000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 122000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 107000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 546000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 122000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 46000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 8000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-08.

Financial data available through: 2025-12-31.

Coverage by financial measure

revenue: No compatible figures in this window
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: 3 of 11 periods available· newest 2025-12-31
Total liabilities: 3 of 11 periods available· newest 2025-12-31
Current assets: 3 of 11 periods available· newest 2025-12-31
Current liabilities: 3 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 3 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 7.17 million

Prior period

−USD 65.36 million

2024-01-01 – 2024-12-31
Current period

−USD 58.2 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-58197000 − -65363000 = 7166000 USD

-65363000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-58197000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · BOUNDLESS BIO, INC. · 2025-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Year-over-year change in Net income: 7166000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -58197000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#3015802 Filing: 000119312526097543 Input fundies:NetIncome: -65363000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#3017549 Filing: 000119312526097543
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 14.14 million

Prior period

−USD 60.84 million

2024-01-01 – 2024-12-31
Current period

−USD 46.7 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-46700000 − -60841000 = 14141000 USD

-60841000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-46700000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · BOUNDLESS BIO, INC. · 2025-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Year-over-year change in Operating cash flow: 14141000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -46700000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2230295 Filing: 000119312526097543 Input fundies:OperatingCashFlow: -60841000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2118901 Filing: 000119312526097543
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-78.5%

Prior period

USD 2.54 million

2024-01-01 – 2024-12-31
Current period

USD 546,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

546000 − 2536000 = -1990000 USD

2536000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
546000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · BOUNDLESS BIO, INC. · 2025-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Year-over-year change in Capital expenditure: -1990000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 546000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2131439 Filing: 000119312526097543 Input fundies:CapitalExpenditure: 2536000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2133282 Filing: 000119312526097543
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.

Values and sources

Revenue values and source evidence
Period	Series	Value	Source evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value	Source evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−USD 49.43 million Exact value Exact value: -49434000 USD 2023-01-01 – 2023-12-31: -49434000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BOUNDLESS BIO, INC. · 2023-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Net Income: -49434000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -49434000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000095017025045725/bold-20241231.htm#2942265 Filing: 000095017025045725 The citation records this snapshot. The page link may show a newer release later.	−USD 46.86 million Exact value Exact value: -46855000 USD 2023-01-01 – 2023-12-31: -46855000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BOUNDLESS BIO, INC. · 2023-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Operating Cash Flow: -46855000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -46855000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000095017025045725/bold-20241231.htm#2122267 Filing: 000095017025045725 The citation records this snapshot. The page link may show a newer release later.	USD 633,000 Exact value Exact value: 633000 USD 2023-01-01 – 2023-12-31: 633000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BOUNDLESS BIO, INC. · 2023-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Capital Expenditure: 633000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 633000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000095017025045725/bold-20241231.htm#2135646 Filing: 000095017025045725 The citation records this snapshot. The page link may show a newer release later.	−USD 47.49 million Calculation and evidence -46855000 − 633000 USD Exact free cash flow: -47488000 USD 2023-01-01 – 2023-12-31: -46855000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 633000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BOUNDLESS BIO, INC. · 2023-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Free cash flow: -47488000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -46855000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000095017025045725/bold-20241231.htm#2122267 Filing: 000095017025045725 Input fundies:CapitalExpenditure: 633000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000095017025045725/bold-20241231.htm#2135646 Filing: 000095017025045725 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 65.36 million Exact value Exact value: -65363000 USD 2024-01-01 – 2024-12-31: -65363000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BOUNDLESS BIO, INC. · 2024-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Net Income: -65363000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65363000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#3017549 Filing: 000119312526097543 The citation records this snapshot. The page link may show a newer release later.	−USD 60.84 million Exact value Exact value: -60841000 USD 2024-01-01 – 2024-12-31: -60841000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BOUNDLESS BIO, INC. · 2024-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Operating Cash Flow: -60841000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -60841000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2118901 Filing: 000119312526097543 The citation records this snapshot. The page link may show a newer release later.	USD 2.54 million Exact value Exact value: 2536000 USD 2024-01-01 – 2024-12-31: 2536000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BOUNDLESS BIO, INC. · 2024-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Capital Expenditure: 2536000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2536000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2133282 Filing: 000119312526097543 The citation records this snapshot. The page link may show a newer release later.	−USD 63.38 million Calculation and evidence -60841000 − 2536000 USD Exact free cash flow: -63377000 USD 2024-01-01 – 2024-12-31: -60841000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 2536000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BOUNDLESS BIO, INC. · 2024-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Free cash flow: -63377000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -60841000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2118901 Filing: 000119312526097543 Input fundies:CapitalExpenditure: 2536000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2133282 Filing: 000119312526097543 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 58.2 million Exact value Exact value: -58197000 USD 2025-01-01 – 2025-12-31: -58197000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BOUNDLESS BIO, INC. · 2025-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Net Income: -58197000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -58197000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#3015802 Filing: 000119312526097543 The citation records this snapshot. The page link may show a newer release later.	−USD 46.7 million Exact value Exact value: -46700000 USD 2025-01-01 – 2025-12-31: -46700000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BOUNDLESS BIO, INC. · 2025-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Operating Cash Flow: -46700000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -46700000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2230295 Filing: 000119312526097543 The citation records this snapshot. The page link may show a newer release later.	USD 546,000 Exact value Exact value: 546000 USD 2025-01-01 – 2025-12-31: 546000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BOUNDLESS BIO, INC. · 2025-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Capital Expenditure: 546000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 546000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2131439 Filing: 000119312526097543 The citation records this snapshot. The page link may show a newer release later.	−USD 47.25 million Calculation and evidence -46700000 − 546000 USD Exact free cash flow: -47246000 USD 2025-01-01 – 2025-12-31: -46700000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 546000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BOUNDLESS BIO, INC. · 2025-12-31 BOUNDLESS BIO, INC. (edgar:1782303) Free cash flow: -47246000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-05T03:08:07Z Snapshot: ec7e8753e54437d1f560de0b2f80c4a4049ec643291cf9e6db64a9dcea4b6196 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1782303?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -46700000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2230295 Filing: 000119312526097543 Input fundies:CapitalExpenditure: 546000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/bold-20251231.htm#2131439 Filing: 000119312526097543 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

13 filings · 749 latest values · 749 originally reported values

Dataset published 2026-11-05. Source filing dates and reporting periods are shown separately.

Identifiers: 0001782303, 1782303, BOLD, edgar:1782303

Also known as BOUNDLESS BIO, INC., Boundless Bio, Inc.

BOUNDLESS BIO, INC.

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

Growth

Profit and cash

Balance sheet

Cash generation